ArticleInternational journal of nanomedicine2021
A Dual pH-Responsive DOX-Encapsulated Liposome Combined with Glucose Administration Enhanced Therapeutic Efficacy of Chemotherapy for Cancer.
Article in International journal of nanomedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 42 citations in OpenAlex.
- Artificial intelligence-assisted design and optimization of stimuli-responsive nanocarriers for smart drug delivery.Materials today. Bio · 2026Review
- Next-generation nanomedicine for cancer therapy: advances, challenges, and future perspectives.Frontiers in chemistry · 2026Review
- Stimuli-Responsive Cell-Mimetic Vesicles for Advanced Pharmaceutical Systems.International journal of nanomedicine · 2026Review
- Dynamic tumor microenvironment remodeling in cancer therapy resistance: molecular mechanisms and translational opportunities.Frontiers in cell and developmental biology · 2026Review
- Functionalized nanomedicines for co-targeting of multiple pathways to efficiently treat thyroid cancer: prospects and challenges.Frontiers in pharmacology · 2026Review
- Recent Advances in pH-Responsive Liposomes: Lessons Learnt and New Directions in Nanomedicine Development.Materials (Basel, Switzerland) · 2025Review
- Dectin-1-targeted pH-responsive liposomal nanoplatform delivering Plantago Asiatica L. acidic polysaccharide for immunomodulation and immunosuppressive breast cancer microenvironment reprogramming.Journal of nanobiotechnology · 2025Article
- Formulation and Evaluation of Liposome-Encapsulated Phenolic Compounds from Olive Mill Waste: Insights into Encapsulation Efficiency, Antioxidant, and Cytotoxic Activities.Molecules (Basel, Switzerland) · 2025Article
- Current Advances in Nanocarriers for Cancer Therapy.International journal of nanomedicine · 2025Review
- Smart Nanoplatforms Responding to the Tumor Microenvironment for Precise Drug Delivery in Cancer Therapy.International journal of nanomedicine · 2024Review
- pH-Responsive Biomaterials for the Treatment of Dental Caries-A Focussed and Critical Review.Pharmaceutics · 2023Review
- Article
- Albumin-Based Zn (II)-Quercetin Enzyme Mimic Scavenging ROS for Protection against Cardiotoxicity Induced by Doxorubicin.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Molecularly engineered tumor acidity-responsive plant toxin gelonin for safe and efficient cancer therapy.Bioactive materials · 2022Article
- Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment.Pharmaceutics · 2022Review
- Aptamer-Modified Erythrocyte Membrane-Coated pH-Sensitive Nanoparticles for c-Met-Targeted Therapy of Glioblastoma Multiforme.Membranes · 2022Article
- pH-Responsive Nanocarriers in Cancer Therapy.Polymers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe acidic microenvironment of cancer can promote tumor metastasis and drug resistance. Acidic tumor microenvironment-targeted therapy is currently an important means for treating tumors, inhibiting metastasis, and overcoming drug resistance. In this study, a dual pH-responsive DOX-encapsulated liposome (DOPE-DVar7-lip@DOX) was designed and fabricated for targeting the acidic tumor microenvironment. On the one hand, the response of acid-sensitive peptide (DVar7) to the acidic tumor microenvironment increased the uptake of liposomes in tumors and prolonged the retention time; on the other hand, the response of acid-sensitive phospholipid (DOPE) to the acidic tumor microenvironment improved the controlled release of DOX in tumors.
methodsThe acid-sensitive peptide DVar7 modified liposomes can be obtained by simple incubation of DSPE-DVar7 with DOX-loaded DOPE liposomes (DOPE-lip@DOX). The tumor targeting of the dual pH-responsive liposome was investigated in vitro and in vivo by near-infrared fluorescence imaging. The tumor therapeutic efficacy of DOPE-DVar7-lip@DOX was evaluated in breast cancer mouse model using the traditional liposome as a control. Moreover, we regulated the tumor microenvironment acidity by injecting glucose to further enhance the therapeutic efficacy of cancer.
resultsDVar7 can allosterically insert into the tumor cell membrane in the acidic tumor microenvironment to enhance the tumor uptake of liposomes and prolong the retention time of liposomes in tumor. In addition, the therapeutic efficacy of pH-responsive liposomes can be further enhanced by glucose injection regulating the acidity of tumor microenvironment. DISCUSSION: DVar7 modified acid-sensitive nanocarriers combined with acidity regulation have great potential to improve drug resistance in clinical practice, thus improving the response rate and therapeutic effect of chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.